Lipella Pharmaceuticals Inc. (LIPO) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
400 N LEXINGTON ST PITTSBURGH, PA 15208 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 3,294 | 5,122 | |||
| Cash and cash equivalent | 3,294 | 5,122 | |||
| Receivables | 32 | 114 | |||
| Prepaid expense | 103 | 564 | |||
| Total current assets: | 3,429 | 5,799 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 135 | 151 | |||
| Property, plant and equipment | 13 | ||||
| Total noncurrent assets: | 148 | 151 | |||
| TOTAL ASSETS: | 3,577 | 5,950 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 215 | 774 | |||
| Accounts payable | 138 | 384 | |||
| Accrued liabilities | 77 | 389 | |||
| Debt | 25 | ||||
| Other liabilities | 250 | ||||
| Other undisclosed current liabilities | 170 | 130 | |||
| Total current liabilities: | 385 | 1,178 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 47 | 96 | |||
| Operating lease, liability | 47 | 96 | |||
| Total noncurrent liabilities: | 47 | 96 | |||
| Total liabilities: | 433 | 1,275 | |||
| Equity | |||||
| Equity, attributable to parent | 3,144 | 4,676 | |||
| Preferred stock | |||||
| Common stock | 1 | 1 | |||
| Additional paid in capital | 13,468 | 10,380 | |||
| Accumulated deficit | (10,324) | (5,705) | |||
| Total equity: | 3,144 | 4,676 | |||
| TOTAL LIABILITIES AND EQUITY: | 3,577 | 5,950 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Revenues | 450 | 184 | ||
| Gross profit: | 450 | 184 | ||
| Operating expenses | (5,196) | (2,774) | ||
| Operating loss: | (4,746) | (2,590) | ||
| Nonoperating income (expense) | 127 | (8) | ||
| Investment income, nonoperating | 138 | 2 | ||
| Interest and debt expense | (11) | (10) | ||
| Loss from continuing operations before equity method investments, income taxes: | (4,630) | (2,607) | ||
| Other undisclosed income from continuing operations before income taxes | 11 | 10 | ||
| Net loss available to common stockholders, diluted: | (4,619) | (2,598) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net loss: | (4,619) | (2,598) | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,619) | (2,598) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.